相关实验视频

Updated: May 6, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.4K

在扩散型大B细胞淋巴瘤中同时使用glofitamab进行放射治疗的耐受性:一个病例报告

Pierre Loap1,2, Natacha Johnson3, Rudy Birsen3

  • 1Department of Radiation Oncology, Institut Curie, Paris, France. pierre.loap@gmail.com.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
|July 2, 2024
PubMed
概括

本案例研究探讨了抗CD20抗体格洛菲他马布与复发性或耐火性扩散性大B细胞淋巴瘤的救援放射治疗的结合. 这种组合显示了耐受性和潜在的疗效,需要进一步研究.

关键词:
双特异性抗体 双特异性抗体免疫学的突触.免疫治疗是一种免疫疗法.的T淋巴细胞.这就是为什么VMAT VMAT.

更多相关视频

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.4K
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.0K

相关概念视频

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.7K